Advertisement

Annals of Surgical Oncology

, Volume 23, Issue 8, pp 2419–2429 | Cite as

Evaluating the Impact of Total Intravenous Anesthesia on the Clinical Outcomes and Perioperative NLR and PLR Profiles of Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

  • Pascal Owusu-AgyemangEmail author
  • Juan P. Cata
  • Keith F. Fournier
  • Acsa M. Zavala
  • Jose Soliz
  • Mike Hernandez
  • Andrea Hayes-Jordan
  • Vijaya Gottumukkala
Gastrointestinal Oncology

Abstract

Purpose

The aim of this study was to assess the impact of total intravenous anesthesia (TIVA) on the perioperative inflammatory profile and clinical outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS–HIPEC).

Methods

A retrospective review of patients undergoing CRS–HIPEC was performed. Patients receiving a combination of preoperative tramadol extended release (ER), celecoxib, and pregabalin, along with combined intraoperative infusions of propofol, dexmedetomidine, lidocaine, and ketamine were classified as receiving a TIVA regimen (TIVA group). The second group consisted of patients receiving volatile–opioid-based anesthesia (VO group). The neutrophil:leukocyte (NLR) and platelet: leukocyte (PLR) ratios were calculated to evaluate the perioperative inflammatory status of both groups. Length of stay (LOS) and complications of both groups were also evaluated.

Results

A total of 213 patients were included in the study—139 in the VO group and 74 in the TIVA group. No statistically significant differences were observed between the groups with regard to their postoperative inflammatory profiles, LOS, or complications by organ system; however, the incidence of renal complications was higher in the TIVA group (8.1 vs. 2.2 %) and approached statistical significance (p = 0.068).

Conclusions

In this retrospective study of patients undergoing CRS–HIPEC, the combined use of preoperative celecoxib, tramadol ER and pregabalin followed by intraoperative TIVA with infusions of propofol, dexmedetomidine, ketamine, and lidocaine was not associated with a reduction in LOS or complications by organ system. Postoperative NLR and PLR profiles were also not significantly impacted.

Keywords

Celecoxib Tramadol Pregabalin Dexmedetomidine Epidural Analgesia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

Pascal Owusu-Agyemang, Juan P. Cata, Keith F. Fournier, Acsa M. Zavala, Jose Soliz, Mike Hernandez, Andrea Hayes-Jordan, and Vijaya Gottumukkala have no conflicts of interest to declare.

Funding

This study was not funded.

References

  1. 1.
    Mortensen K, Nilsson M, Slim K, et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014;101(10):1209–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Mathiesen O, Dahl B, Thomsen BA, et al. A comprehensive multimodal pain treatment reduces opioid consumption after multilevel spine surgery. Eur Spine J. 2013;22(9):2089–96.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Khan SK, Malviya A, Muller SD, et al. Reduced short-term complications and mortality following enhanced recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures. Acta Orthop. 2014;85(1):26–31.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Corcoran TB, Engel A, Sakamoto H, O’Shea A, O’Callaghan-Enright S, Shorten GD. The effects of propofol on neutrophil function, lipid peroxidation and inflammatory response during elective coronary artery bypass grafting in patients with impaired ventricular function. Br J Anaesth. 2006;97(6):825–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004;32(6):1322–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Roytblat L, Talmor D, Rachinsky M, et al. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. Anesth Analg. 1998;87(2):266–71.PubMedGoogle Scholar
  7. 7.
    Herroeder S, Pecher S, Schonherr ME, et al. Systemic lidocaine shortens length of hospital stay after colorectal surgery: a double-blinded, randomized, placebo-controlled trial. Ann Surg. 2007;246(2):192–200.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Begossi G, Gonzalez-Moreno S, Ortega-Perez G, Fon LJ, Sugarbaker PH. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol. 2002;28(1):80–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Medina Fernandez FJ, Munoz-Casares FC, Arjona-Sanchez A, et al. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC. Ann Surg Oncol. 2015;22(4):1332–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Bugada D, Allegri M, Lavand’homme P, De Kock M, Fanelli G. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. Biomed Res Int. 2014;2014:142425.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 2014;110(8):1930–35.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kusamura S, Baratti D, Hutanu I, et al. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2015;41(8):1097–105.CrossRefPubMedGoogle Scholar
  13. 13.
    Fajardo AM, Piazza GA. Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol. 2015;309(2):G59-70.CrossRefPubMedGoogle Scholar
  14. 14.
    Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth. 2014;113 Suppl 1:i82–87.CrossRefPubMedGoogle Scholar
  15. 15.
    Forget P, Machiels JP, Coulie PG, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013;20 Suppl 3:S650–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Forget P, Vandenhende J, Berliere M, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110(6):1630–35.CrossRefPubMedGoogle Scholar
  17. 17.
    Byrne K, Levins KJ, Buggy DJ. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis? Can J Anaesth. 2015;23.Google Scholar
  18. 18.
    Kajdi ME, Beck-Schimmer B, Held U, Kofmehl R, Lehmann K, Ganter MT. Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience. World J Surg Oncol. 2014;12:136.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Colantonio L, Claroni C, Fabrizi L, et al. A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg. 2015;19(4):722–29.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang H, Zhang L, Zhu K, et al. Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS One. 2015;10(5):e0126496.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Raffetti E, Donato F, Castelli F, Maggiolo F, Carosi G, Quiros-Roldan E. The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study. Infect Agent Cancer. 2015;10:34.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Neal CP, Cairns V, Jones MJ, et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases. Med Oncol. 2015;32(5):144.CrossRefPubMedGoogle Scholar
  23. 23.
    Yardeni IZ, Beilin B, Mayburd E, Levinson Y, Bessler H. The effect of perioperative intravenous lidocaine on postoperative pain and immune function. Anesth Analg. 2009;109(5):1464–69.CrossRefPubMedGoogle Scholar
  24. 24.
    Li B, Li Y, Tian S, et al. Anti-inflammatory effects of perioperative dexmedetomidine administered as an adjunct to general anesthesia: a meta-analysis. Sci Rep. 2015;5:12342.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Dale O, Somogyi AA, Li Y, Sullivan T, Shavit Y. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg. 2012;115(4):934–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhao H, Feng Y, Wang Y, Yang B, Xing Z. Comparison of different loading dose of celecoxib on postoperative anti-inflammation and analgesia in patients undergoing endoscopic nasal surgery-200 mg is equivalent to 400 mg. Pain Med. 2011;12(8):1267–75.CrossRefPubMedGoogle Scholar
  27. 27.
    Bach F, Grundmann U, Bauer M, et al. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand. 2002;46(10):1227–35.CrossRefPubMedGoogle Scholar
  28. 28.
    Moselli NM, Baricocchi E, Ribero D, Sottile A, Suita L, Debernardi F. Intraoperative epidural analgesia prevents the early proinflammatory response to surgical trauma. Results from a prospective randomized clinical trial of intraoperative epidural versus general analgesia. Ann Surg Oncol. 2011;18(10):2722–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Lindholm EE, Aune E, Seljeflot I, Otterstad JE, Kirkeboen KA. Biomarkers of inflammation in major vascular surgery: a prospective randomised trial. Acta Anaesthesiol Scand. 2015;59(6):773–87.CrossRefPubMedGoogle Scholar
  30. 30.
    Tsimogiannis KE, Tellis CC, Tselepis AD, Pappas-Gogos GK, Tsimoyiannis EC, Basdanis G. Toll-like receptors in the inflammatory response during open and laparoscopic colectomy for colorectal cancer. Surg Endosc. 2012;26(2):330–36.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang HL, Zhang WH, Lei WF, Zhou CQ, Ye T. The inhibitory effect of lidocaine on the release of high mobility group box 1 in lipopolysaccharide-stimulated macrophages. Anesth Analg. 2011;112(4):839–44.CrossRefPubMedGoogle Scholar
  32. 32.
    Kim MH, Hahm TS. Plasma levels of interleukin-6 and interleukin-10 are affected by ketorolac as an adjunct to patient-controlled morphine after abdominal hysterectomy. Clin J Pain. 2001;17(1):72–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Dale O, Somogyi AA, Li YB, Sullivan T, Shavit Y. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg. 2012;115(4):934–43.CrossRefPubMedGoogle Scholar
  34. 34.
    Forget P, Machiels J-P, Coulie P, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013;20 Suppl 3:S650–60.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Pascal Owusu-Agyemang
    • 1
    Email author
  • Juan P. Cata
    • 1
    • 4
  • Keith F. Fournier
    • 2
  • Acsa M. Zavala
    • 1
  • Jose Soliz
    • 1
  • Mike Hernandez
    • 3
  • Andrea Hayes-Jordan
    • 2
  • Vijaya Gottumukkala
    • 1
  1. 1.Department of Anesthesiology and Perioperative MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Anesthesiology and Surgical Oncology Research GroupHoustonUSA

Personalised recommendations